RESUMO
There is today an exponential increase in prevalence of type 2 diabetes mellitus (T2DM), especially in young people. This downward shift in age of onset of T2DM has been shown by abundant evidence to be due to an increase in obesity among the young, the latter mainly attributable to unhealthy dietary habits and a sedentary lifestyle. It is therefore obvious that the prevention of diabetes rather its treatment is of is paramount importance. In the past decade, because concerns about the safety of antidiabetic agents took precedence over the issue of efficacy, almost all studies have been diabetes CVOTs and not traditional CVOTs. Until 2015, the evidence showed that antidiabetic agents are effective in terms of reduction of microvascular, as opposed to macrovascular, complications. However, following publication of the results of some new studies, it became clear that the new class of antidiabetic drugs, e.g., SGLT 2 inhibitors and GLP-1 agonists, are also effective in reducing cardiovascular disease (CVD). In the coming decade, numerous health challenges are expected to arise, the most important being the greater expansion of the therapeutic armamentarium for T2DM and the adoption of strategies for prevention of CVDs. In parallel, the new generation of antidiabetic agents will target the recently investigated pathophysiologic disorders of diabetes, while, ideally, treatments should include smart drugs without side effects.
Assuntos
Doenças Cardiovasculares/tratamento farmacológico , Estudos Clínicos como Assunto , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/farmacologia , Doenças Cardiovasculares/história , Estudos Clínicos como Assunto/história , Diabetes Mellitus Tipo 2/história , História do Século XXI , Humanos , Hipoglicemiantes/históriaAssuntos
Estudos Clínicos como Assunto , Neuroma Acústico/cirurgia , Procedimentos Neurocirúrgicos , Estudos Clínicos como Assunto/história , História do Século XX , Humanos , Índia , Neuroma Acústico/história , Procedimentos Neurocirúrgicos/história , Procedimentos Neurocirúrgicos/métodos , Procedimentos Neurocirúrgicos/normasRESUMO
We describe the National Institutes of Health rare disease consortium for Prader-Willi syndrome (PWS) developed to address concerns regarding medical care, diagnosis, growth and development, awareness, and natural history. PWS results from errors in genomic imprinting leading to loss of paternally expressed genes due to 15q11-q13 deletion, maternal disomy 15 or imprinting defects. The 8 year study was conducted at four national sites on individuals with genetically confirmed PWS and early-onset morbid obesity (EMO) with data accumulated to gain a better understanding of the natural history, cause and treatment of PWS. Enrollment of 355 subjects with PWS and 36 subjects with EMO began in September 2006 with study completion in July 2014. Clinical, genetic, cognitive, behavior, and natural history data were systematically collected along with PWS genetic subtypes, pregnancy and birth history, mortality, obesity, and cognitive status with study details as important endpoints in both subject groups. Of the 355 individuals with PWS, 217 (61%) had the 15q11-q13 deletion, 127 (36%) had maternal disomy 15, and 11 (3%) had imprinting defects. Six deaths were reported in our PWS cohort with 598 cumulative years of study exposure and one death in the EMO group with 42 years of exposure. To our knowledge, this description of a longitudinal study in PWS represents the largest and most comprehensive cohort useful for investigators in planning comparable studies in other rare disorders. Ongoing studies utilizing this database should have a direct impact on care and services, diagnosis, treatment, genotype-phenotype correlations, and clinical outcomes in PWS.
Assuntos
Estudos Clínicos como Assunto , Obesidade Mórbida/diagnóstico , Obesidade Mórbida/genética , Síndrome de Prader-Willi/diagnóstico , Síndrome de Prader-Willi/genética , Doenças Raras/diagnóstico , Doenças Raras/genética , Idade de Início , Estudos Clínicos como Assunto/história , História do Século XXI , Humanos , Mortalidade , National Institutes of Health (U.S.) , Obesidade Mórbida/epidemiologia , Avaliação de Resultados em Cuidados de Saúde , Síndrome de Prader-Willi/epidemiologia , Doenças Raras/epidemiologia , Estados UnidosRESUMO
This article describes the use of poison trials, in which an animal or a condemned criminal was poisoned, to test antidotes in sixteenth-century Europe. In contrast to most drug testing in medieval and early modern Europe, which was gathered in the normal course of therapeutic experience, the poison trial was a contrived, deliberate event. I argue that poison trials had an important function in both medical testing and medical writing in the period between 1524-1580. While poison trials dated back to antiquity, they tended to be described in medieval texts as theoretical possibilities rather than empirical tests that had already occurred. In contrast, early modern physicians conducted poison trials and described them as anecdotes in medical texts. Although physicians did not explicitly separate poison trials from evidence gathered in the course of regular therapeutic experience, they did imbue the outcome of poison trials with considerable epistemological weight.